Metabolic Cost of Walking With Passive vs. Powered Microprocessor Controlled Knees

September 8, 2021 updated by: Össur Ehf

Metabolic Cost of Level Ground Walking With Passive vs. Powered Microprocessor Controlled Knees for Higher Active TF Amputees

This study is conducted to evaluate the efficacy of the Power Knee Mainstream Dynamic compared to passive microprocessor-controlled knees (MPKs) regarding metabolic cost for high active transfemoral amputees.The test is of a single group repeated measures crossover design. The primary endpoint is the difference in MET/HRI-VO2 index between conditions. Subjects are measured on their prescribed device at visit 1, be fitted to the PKM which they wear as their primary prosthesis for one week before coming for visit 2 and being measured again on the PKM.

Study Overview

Detailed Description

The metabolic cost of ambulation for individuals living with a lower limb amputation is significantly increased compared to able-bodied individuals. Individuals living with transfemoral amputation have shown up to 65% more exertion to generate half the ambulation speed of able-bodied individuals.

The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face. This study aims to evaluate this indirectly by measuring the heart rate during level ground walking on the Power Knee Mainstream - Dynamic compared to a passive MPK.

Previous studies reported in the literature on previous versions of the Power Knee have shown that it provides active flexion and extension during walking2, 3, 4 and more symmetric gait5 compared to passive microprocessor-controlled knees (MPKs). By providing increased symmetry and active swing during level ground walking the knee is meant to lower the effort needed by the transfemoral prosthesis user to swing the leg forward and thereby lower the metabolic cost of level ground walking.

This underpins the hypothesis being tested in this investigation, that the Power Knee Mainstream - Dynamic enables the user to walk with less metabolic cost compared to passive MPKs.

A pilot investigation that was conducted with 5 subjects indicated that the Power Knee Mainstream - Dynamic enabled users to walk on level ground with less metabolic cost compared to passive MPKs, however the difference did not reach statistical significance. The same study procedure will be used in this study with sufficient sample size to achieve the statistical power needed, which was determined in a power analysis using data form the pilot study mentioned above.

The primary objective of this study is to evaluate the efficacy of the investigational device compared to passive microprocessor-controlled knees (MPKs) regarding metabolic cost for high active transfemoral amputees.

The test is of a single group repeated measures crossover design. Amputees are a small proportion of the general population. The primary endpoint is the difference in MET/HRI-VO2 index between conditions.

Testing takes place in Össur HQ in Iceland as well as in Össur facility in Germany, the collective sample size in both sites is 20 subjects.

Subjects are measured on their prescribed device at visit 1, be fitted to the PKM which they wear as their primary prosthesis for one week before coming for visit 2 and being measured again on the PKM.

If a subject in the study is a current PKM user the procedure will apply in reverse and they will be provided with a Rheo knee to act as a comparator.

Prior to the first visit subjects will be contacted via telephone and asked screening questions, if they fit the inclusion criteria they will be booked for study visit 1. They will receive instructions to consume no alcohol and perform no exercise for 24 hours before study visit 1, the same applies to visit 2. In addition, they will be instructed to consume no caffeine prior to the visits (same day) or drink the same amount before both visits and keep the same routine the 24 hours prior to visit 1 and 2 (breakfast, water/drink consumption etc.).

During the one week follow up, subjects will be called via telephone to check the status of the device and the alignment and if there are issues identified they will be asked to come in to correct those.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Bavaria
      • Bayreuth, Bavaria, Germany, 95448
        • Össur Germany
      • Reykjavík, Iceland, 110
        • Össur HQ

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 50Kg< body weight < 116Kg
  • Cognitive ability to understand all instructions and questionnaires in the study;
  • Higher active unilateral trans-femoral amputees
  • Allows for 37mm knee center height to dome of pyramid alignment to allow for symmetrical knee height to sound side
  • Willing and able to participate in the study and follow the protocol
  • Comfortable and stable socket fit
  • No socket issues/changes in the last 6 weeks
  • No residual limb pain affecting functional ability
  • Users with at least 6 months experience on a prosthesis

Exclusion Criteria:

  • Hip disarticulation amputees
  • Bilateral amputees
  • Users with Osseointegrated prosthesis
  • Users with co-morbidities in the contra-lateral limb, which significantly affect their functional mobility
  • Users taking beta-adrenergic blocking agents (beta blockers) or other medication for heart rate control e.g. Verapamil & Digoxin.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Power Knee Mainstream Dynamic
Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
Active Comparator: Passive MPK
Any passive microprocessor controlled prosthetic knee on the market

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Metabolic cost
Time Frame: 1 week
MET/HRI-VO2 index
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 26, 2021

Primary Completion (Actual)

August 25, 2021

Study Completion (Actual)

August 25, 2021

Study Registration Dates

First Submitted

September 3, 2021

First Submitted That Met QC Criteria

September 8, 2021

First Posted (Actual)

September 17, 2021

Study Record Updates

Last Update Posted (Actual)

September 17, 2021

Last Update Submitted That Met QC Criteria

September 8, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • CII2021050747

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Amputation

Clinical Trials on Power Knee Mainstream Dynamic

3
Subscribe